1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Urinary Incontinence - Pipeline Review, H1 2016

Urinary Incontinence - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 73 pages

Urinary Incontinence - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Urinary Incontinence - Pipeline Review, H1 2016’, provides an overview of the Urinary Incontinence pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Urinary Incontinence, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Urinary Incontinence
- The report reviews pipeline therapeutics for Urinary Incontinence by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Urinary Incontinence therapeutics and enlists all their major and minor projects
- The report assesses Urinary Incontinence therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Urinary Incontinence

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Urinary Incontinence
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Urinary Incontinence pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Urinary Incontinence - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Urinary Incontinence Overview 8
Therapeutics Development 9
Pipeline Products for Urinary Incontinence - Overview 9
Pipeline Products for Urinary Incontinence - Comparative Analysis 10
Urinary Incontinence - Therapeutics under Development by Companies 11
Urinary Incontinence - Therapeutics under Investigation by Universities/Institutes 12
Urinary Incontinence - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Urinary Incontinence - Products under Development by Companies 16
Urinary Incontinence - Products under Investigation by Universities/Institutes 17
Urinary Incontinence - Companies Involved in Therapeutics Development 18
Astellas Pharma Inc. 18
Celogos 19
Cook MyoSite Incorporated 20
Evotec AG 21
FemmePharma Global Healthcare, Inc. 22
GTx, Inc. 23
Innovacell Biotechnologie AG 24
Taiho Pharmaceutical Co., Ltd. 25
TheraVida, Inc. 26
Urinary Incontinence - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Combination Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
(mirabegron + solifenacin succinate) - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
ASP-2205 - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Cell Therapy for Urinary Incontinence - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
enobosarm - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
ICES-13 - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
oxybutynin hydrochloride - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
Prof-003 - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
RCD-1 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
Small Molecule to Antagonize P2X3 and P2X2/3 for Inflammatory Pain, Neuropathic Pain and Urinary Incontinence - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
Stem Cell Therapy for Fecal Incontinence, Ischemic Heart Failure and Urological Diseases - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
TAS-303 - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
THVD-201 - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
THVD-202 - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
Urinary Incontinence - Recent Pipeline Updates 53
Urinary Incontinence - Dormant Projects 61
Urinary Incontinence - Discontinued Products 64
Urinary Incontinence - Product Development Milestones 65
Featured News and Press Releases 65
Jan 13, 2016: GTx Announces Initiation of Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence 65
Oct 13, 2015: GTx Receives FDA Clearance to Initiate Clinical Trial in Stress Urinary Incontinence 65
May 17, 2015: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial 66
Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg 67
Jan 03, 2013: TheraVida Announces Positive Top-line Phase II Results For Tolenix In Patients With Overactive Bladder And Urge Urinary Incontinence 67
Mar 15, 2012: Innovacell to Present Phase IIb Trial Results Of ICES13 At MedTech Investing Europe Conference 68
Dec 05, 2011: Pfizer's Toviaz Shows Positive Top-Line Primary Endpoint Result in Study of Overactive Bladder in Vulnerable Elderly Patients 68
Nov 08, 2011: Pfizer Announces Positive Top-Line Primary Endpoint Results Of Toviaz In Overactive Bladder Including Nocturnal Urinary Urgency 69
Aug 30, 2011: Innovacell passes a further milestone 69
May 16, 2011: TheraVida Initiates Phase II Trial Of THVD-201 For Overactive Bladder And Urinary Incontinence 70
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 72
Disclaimer 73

List of Tables
Number of Products under Development for Urinary Incontinence, H1 2016 9
Number of Products under Development for Urinary Incontinence - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Investigation by Universities/Institutes, H1 2016 17
Urinary Incontinence - Pipeline by Astellas Pharma Inc., H1 2016 18
Urinary Incontinence - Pipeline by Celogos, H1 2016 19
Urinary Incontinence - Pipeline by Cook MyoSite Incorporated, H1 2016 20
Urinary Incontinence - Pipeline by Evotec AG, H1 2016 21
Urinary Incontinence - Pipeline by FemmePharma Global Healthcare, Inc., H1 2016 22
Urinary Incontinence - Pipeline by GTx, Inc., H1 2016 23
Urinary Incontinence - Pipeline by Innovacell Biotechnologie AG, H1 2016 24
Urinary Incontinence - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016 25
Urinary Incontinence - Pipeline by TheraVida, Inc., H1 2016 26
Assessment by Monotherapy Products, H1 2016 27
Assessment by Combination Products, H1 2016 28
Number of Products by Stage and Target, H1 2016 30
Number of Products by Stage and Mechanism of Action, H1 2016 32
Number of Products by Stage and Route of Administration, H1 2016 34
Number of Products by Stage and Molecule Type, H1 2016 36
Urinary Incontinence Therapeutics - Recent Pipeline Updates, H1 2016 53
Urinary Incontinence - Dormant Projects, H1 2016 61
Urinary Incontinence - Dormant Projects (Contd..1), H1 2016 62
Urinary Incontinence - Dormant Projects (Contd..2), H1 2016 63
Urinary Incontinence - Discontinued Products, H1 2016 64

List of Figures
Number of Products under Development for Urinary Incontinence, H1 2016 9
Number of Products under Development for Urinary Incontinence - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 14
Assessment by Monotherapy Products, H1 2016 27
Number of Products by Targets, H1 2016 29
Number of Products by Stage and Targets, H1 2016 29
Number of Products by Mechanism of Actions, H1 2016 31
Number of Products by Stage and Mechanism of Actions, H1 2016 31
Number of Products by Routes of Administration, H1 2016 33
Number of Products by Stage and Routes of Administration, H1 2016 33
Number of Products by Molecule Types, H1 2016 35
Number of Products by Stage and Molecule Types, H1 2016 35

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) - Pipeline Review, H2 2016

B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) - Pipeline Review, H2 2016’, provides ...

Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Pipeline Review, H2 2016

Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Adrenocorticotropic Hormone ...

Lupus Nephritis - Pipeline Review, H2 2016

Lupus Nephritis - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Lupus Nephritis - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Lupus Nephritis - Pipeline Review, H2 2016’, provides an overview of the Lupus Nephritis pipeline landscape. The report ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.